Fluphenazine decanoate
CAS : 5002-47-1
Ref. 3D-FF34284
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
- 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-, decanoate (ester)
- 2-(4-{3-[2-(Trifluormethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyldecanoat
- 2-(4-{3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl}-1-piperazinyl)ethyl decanoate
- 2-(4-{3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate
- Dapotum D
- Decanoic Acid 2-(4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl Ester
- Decanoic Acid 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl Ester
- Decanoic acid, 2-[4-[3-[2- (trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazin yl]ethyl ester
- Depot
- Flufenazine decanoate
- Voir d'autres synonymes
- Fluorophenazine decanoate
- Fluphenazine Depot
- Lyogen
- Modecate
- Moditen depot
- NSC 169510
- Prolixin decanoate
- Qd 10733
- Sq 10733
- décanoate de 2-(4-{3-[2-(trifluorométhyl)-10H-phénothiazin-10-yl]propyl}pipérazin-1-yl)éthyle
Fluphenazine decanoate is an injectable antipsychotic medication that belongs to the class of phenothiazines. Fluphenazine decanoate has anti-psychotic effects and can be used for the treatment of schizophrenia. It inhibits the synthesis of dopamine by blocking postsynaptic dopamine receptors and blocks postsynaptic serotonin receptors. Fluphenazine decanoate is metabolized into fluphenazine, which is responsible for its therapeutic effects. The drug has been shown to statistically increase serum prolactin levels in patients with schizophrenia when compared to placebo. Fluphenazine decanoate also has a toxic effect on epidermal cells, leading to intermolecular hydrogen bonding with DNA, which may cause oxidative injury to skin cells.